These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 28199990)

  • 1. Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression.
    Giuliani M; Janji B; Berchem G
    Oncotarget; 2017 Apr; 8(14):24031-24044. PubMed ID: 28199990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.
    Görgün G; Samur MK; Cowens KB; Paula S; Bianchi G; Anderson JE; White RE; Singh A; Ohguchi H; Suzuki R; Kikuchi S; Harada T; Hideshima T; Tai YT; Laubach JP; Raje N; Magrangeas F; Minvielle S; Avet-Loiseau H; Munshi NC; Dorfman DM; Richardson PG; Anderson KC
    Clin Cancer Res; 2015 Oct; 21(20):4607-18. PubMed ID: 25979485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.
    Benson DM; Bakan CE; Mishra A; Hofmeister CC; Efebera Y; Becknell B; Baiocchi RA; Zhang J; Yu J; Smith MK; Greenfield CN; Porcu P; Devine SM; Rotem-Yehudar R; Lozanski G; Byrd JC; Caligiuri MA
    Blood; 2010 Sep; 116(13):2286-94. PubMed ID: 20460501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone marrow-derived mesenchymal stem cells inhibit CD8
    Liu Z; Mi F; Han M; Tian M; Deng L; Meng N; Luo J; Fu R
    Clin Exp Immunol; 2021 Jul; 205(1):53-62. PubMed ID: 33735518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer.
    Dai C; Lin F; Geng R; Ge X; Tang W; Chang J; Wu Z; Liu X; Lin Y; Zhang Z; Li J
    Oncotarget; 2016 Mar; 7(9):10332-44. PubMed ID: 26871284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.
    Benson DM; Bakan CE; Zhang S; Collins SM; Liang J; Srivastava S; Hofmeister CC; Efebera Y; Andre P; Romagne F; Bléry M; Bonnafous C; Zhang J; Clever D; Caligiuri MA; Farag SS
    Blood; 2011 Dec; 118(24):6387-91. PubMed ID: 22031859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.
    Tai YT; Li XF; Catley L; Coffey R; Breitkreutz I; Bae J; Song W; Podar K; Hideshima T; Chauhan D; Schlossman R; Richardson P; Treon SP; Grewal IS; Munshi NC; Anderson KC
    Cancer Res; 2005 Dec; 65(24):11712-20. PubMed ID: 16357183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers.
    Liu Y; Cheng Y; Xu Y; Wang Z; Du X; Li C; Peng J; Gao L; Liang X; Ma C
    Oncogene; 2017 Nov; 36(44):6143-6153. PubMed ID: 28692048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade.
    Hallett WH; Jing W; Drobyski WR; Johnson BD
    Biol Blood Marrow Transplant; 2011 Aug; 17(8):1133-45. PubMed ID: 21536144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.
    Hsu J; Hodgins JJ; Marathe M; Nicolai CJ; Bourgeois-Daigneault MC; Trevino TN; Azimi CS; Scheer AK; Randolph HE; Thompson TW; Zhang L; Iannello A; Mathur N; Jardine KE; Kirn GA; Bell JC; McBurney MW; Raulet DH; Ardolino M
    J Clin Invest; 2018 Oct; 128(10):4654-4668. PubMed ID: 30198904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Built-in" PD-1 blocker to rescue NK-92 activity from PD-L1-mediated tumor escape mechanisms.
    Mensali N; Dillard P; Fayzullin A; Köksal H; Gaudernack G; Kvalheim G; Inderberg EM; Wälchli S
    FASEB J; 2021 Sep; 35(9):e21750. PubMed ID: 34424568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells.
    Jungkunz-Stier I; Zekl M; Stühmer T; Einsele H; Seggewiss-Bernhardt R
    Leuk Lymphoma; 2014 Jan; 55(1):168-76. PubMed ID: 23573828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells.
    Guo Y; Feng X; Jiang Y; Shi X; Xing X; Liu X; Li N; Fadeel B; Zheng C
    Oncotarget; 2016 Jul; 7(30):48360-48374. PubMed ID: 27356741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
    Chen N; Fang W; Zhan J; Hong S; Tang Y; Kang S; Zhang Y; He X; Zhou T; Qin T; Huang Y; Yi X; Zhang L
    J Thorac Oncol; 2015 Jun; 10(6):910-23. PubMed ID: 25658629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
    Anderson KC
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S3-8. PubMed ID: 16344099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.
    Benson DM; Cohen AD; Jagannath S; Munshi NC; Spitzer G; Hofmeister CC; Efebera YA; Andre P; Zerbib R; Caligiuri MA
    Clin Cancer Res; 2015 Sep; 21(18):4055-61. PubMed ID: 25999435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.
    Tai YT; Cho SF; Anderson KC
    Front Immunol; 2018; 9():1822. PubMed ID: 30147691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function.
    Gandhi AK; Kang J; Capone L; Parton A; Wu L; Zhang LH; Mendy D; Lopez-Girona A; Tran T; Sapinoso L; Fang W; Xu S; Hampton G; Bartlett JB; Schafer P
    Curr Cancer Drug Targets; 2010 Mar; 10(2):155-67. PubMed ID: 20088798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization.
    Pesce S; Greppi M; Tabellini G; Rampinelli F; Parolini S; Olive D; Moretta L; Moretta A; Marcenaro E
    J Allergy Clin Immunol; 2017 Jan; 139(1):335-346.e3. PubMed ID: 27372564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.
    Wolschke C; Stübig T; Hegenbart U; Schönland S; Heinzelmann M; Hildebrandt Y; Ayuk F; Atanackovic D; Dreger P; Zander A; Kröger N
    Exp Hematol; 2013 Feb; 41(2):134-142.e3. PubMed ID: 23085463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.